Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
about
Lymphoma Immunotherapy: Current StatusNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewApproach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryDiffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Lenalidomide for the treatment of B-cell lymphoma.Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacyOral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case reportAddition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphomaAggressive B-cell lymphomas: how many categories do we need?Expanding role of lenalidomide in hematologic malignanciesTreatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men.Lenalidomide in multiple myeloma: Current status and future potential.Combination strategies to enhance antitumor ADCC.Lenalidomide in diffuse large B-cell lymphomas.Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma.Lenalidomide in lymphomas and chronic lymphocytic leukemia.Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients.A clinician's guide to double hit lymphomas.A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin LymphomaNovelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.The evolving role of lenalidomide in non-Hodgkin lymphoma.Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.Lenalidomide in diffuse large B-cell lymphoma.Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.Trial Watch: Lenalidomide-based immunochemotherapy.Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
P2860
Q26782902-BA90E74C-0C4B-4C89-B416-B74D40F4950BQ27304386-B4B14CF2-72F9-4AB8-AFE5-34FFE8C8B2E7Q28088365-B37555CB-2C8B-469F-988E-9B8376145E0EQ30235296-A1931865-A011-4F31-8450-E8E579C0752BQ30249007-FA973A1C-402F-4D4A-B2F6-3D22FF6B3CAFQ30659342-F9066DB6-E222-4200-A3D7-71B809A3E656Q33406742-3CA7BE91-FB85-4C7B-8C13-9CC56DA717E7Q33407102-E5A3C877-F4D5-408E-9DF3-ABB0D5E30610Q33408772-EC0D230C-C050-4CC9-9233-D798D6979DADQ33413210-F8586079-858B-43DD-AE41-72B95749751DQ34253548-841D883A-0205-46CA-8CE5-E877CDF0D715Q34314074-BDE24885-DC14-4052-8A1B-36A1ABB3A704Q34819534-80C0DDA8-12E7-4B71-A631-9A3F52547C19Q35527893-3827A7C4-8CC6-4C94-AE03-21129E198A9BQ35592305-0B80DF06-FCB8-47C5-94AA-9C0072BEA52FQ37178611-3A7089DA-F90A-405E-B939-2D4B0A3BB1E5Q37212903-63F62E55-59FC-4C68-9C9F-DDA463DF1595Q37449333-273F83BC-650E-464C-9BD4-EDBEE6408913Q38013995-70E2715E-C260-4D91-B15F-73C9CFC6C8CEQ38014085-A8D7D8E9-7B5C-4FA3-BAB8-9B28F48EFA04Q38026039-D743AE30-1089-45FA-B5F1-7CFBC691953FQ38034939-568554AB-5F02-4703-ADC1-C5DAA710C32AQ38077277-F4442268-FDE8-4E57-9526-6F3242FEBC6AQ38210641-B33A0D98-6DB0-4DBE-8535-3D71D332F277Q38296091-E7910D38-3487-44EC-803A-C74780C6FEF2Q38364912-F664BEF8-9C44-4C48-82B1-3B382C91B75FQ38551337-E171EEF4-37C8-4E3E-B86B-F09526CFD472Q38594364-BEE1F4EC-A96D-4781-A867-639D107624DCQ38744704-A7396C39-3695-48C8-AB6E-47ED2F227085Q39138108-D0086C45-E3AB-496A-B3AD-FF3DB9EC6E75Q39938060-376F1641-55B5-4948-A60D-68DDA9DCB1E1Q40022297-B33970E0-B5E4-4AB4-846D-2E33E5840582Q40831512-9283F2CC-8973-481A-B71B-E57CE5DFD828Q42361544-89F5D33D-6B80-4516-B6FC-A535653A1003Q42384346-68AE782A-E17E-4021-A106-B7A1E8FF6F9AQ42737828-834471D2-BACC-4741-BA7D-ED4D54153B9BQ43757715-AD2C2F11-C90E-45A4-94B0-9BA59D9DC7F9Q44166662-C7F66ADA-50EC-4293-A9BF-D847276210B5Q44482782-FC692CD2-C7E9-49CD-B07C-A1322C6AABE1Q46111102-5A1A345E-4A71-4114-AE25-BB5F1A07DF62
P2860
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Combination of lenalidomide an ...... ell lymphoma: a phase 2 trial.
@ast
Combination of lenalidomide an ...... ell lymphoma: a phase 2 trial.
@en
type
label
Combination of lenalidomide an ...... ell lymphoma: a phase 2 trial.
@ast
Combination of lenalidomide an ...... ell lymphoma: a phase 2 trial.
@en
prefLabel
Combination of lenalidomide an ...... ell lymphoma: a phase 2 trial.
@ast
Combination of lenalidomide an ...... ell lymphoma: a phase 2 trial.
@en
P2093
P50
P1476
Combination of lenalidomide an ...... ell lymphoma: a phase 2 trial.
@en
P2093
Alessandro Broccoli
Cinzia Pellegrini
Federica Quirini
Letizia Gandolfi
Stefano Pileri
Vittorio Stefoni
P304
P356
10.1016/J.CLML.2011.02.001
P407
P577
2011-05-04T00:00:00Z